FFS

Despite slowing growth and regulatory headwinds, Medicare Advantage enrollment remains strong and outlook positive

Retrieved on: 
Tuesday, March 5, 2024
Preferred provider organization, SNP, Special needs plan, United States Census Bureau, CMS, Chronic condition, Management, Medicare Advantage, Growth, FFS, American International Group, Medicare, Region, Optimism, CBSA, Health insurance

CHICAGO, March 5, 2024 /PRNewswire/ -- Chartis, a comprehensive healthcare advisory firm, today announced the release of its annual 2024 Medicare Advantage competitive enrollment report. This year's report is a collaboration between Chartis and HealthScape Advisors, A Chartis Company. Together, they help payers and providers manage transformational change in a rapidly evolving healthcare ecosystem that is increasingly defined by payer-provider convergence.

Key Points: 
  • This year's edition of the report shows that despite strong enrollment gains, market growth appears to be slowing.
  • The Medicare Advantage market grew by 1.7 million beneficiaries (+5.4%) in 2023, slowing down from the record growth of 2.7 million (+9.4%) in 2022.
  • This ongoing enrollment growth is fueled by an increasing senior market but is overshadowed by regulatory pressures, declining quality scores, and rising medical costs.
  • In addition to top-line enrollment statistics and executive sentiment, Chartis' 2024 Medicare Advantage report analyzed:
    Special Needs Plan (SNP) growth: SNP enrollment has surged, adding 1.2 million members.

Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS™ CELLEX™ Photopheresis System Treatment at the 2024 Tandem Meetings

Retrieved on: 
Wednesday, February 21, 2024
Thermal, Bangladesh Technical Education Board, Pulmonary embolism, Hypotension, Mallinckrodt, Anemia, Month, NIH, PUVA, Meta-analysis, Erythroderma, Excipient, Safety, PUVA therapy, Pain, Infection, Quality of life (healthcare), Deep vein thrombosis, Photopheresis, Artifact, FFS, ECP, Risk, OS, Graft-versus-host disease, Society, Extracorporeal, Methoxsalen, Patient, Systematic review, Burns, Transplant, Massachusetts General Hospital, Sunlight, Literature, Clutch (eggs), Environment, Pharmaceutical industry

DUBLIN, Feb. 21, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced a poster presentation of findings from a systematic literature review and meta-analysis of the safety, efficacy, and real-world outcomes of extracorporeal photopheresis (ECP) treatment for patients with steroid-refractory chronic graft-versus-host disease (SR-cGvHD).1 An analysis of 47 studies reporting on the THERAKOS™ CELLEX™ Photopheresis System showed that treatment of SR-cGvHD with ECP was associated with improvements in patients' overall survival (OS), failure-free survival (FFS), and overall response rate (ORR).1 The results will be shared in a poster presentation at the 2024 Tandem Meetings, the combined Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) taking place February 21-24, 2024 in San Antonio, TX.

Key Points: 
  • Skin-specific response at Months 2-3 and at Months 4-6 were 34.86% (95% CI: 13.26-65.21) and 54.22% (95% CI: 35.67-71.67), respectively.
  • Outcomes may be influenced by therapies not evaluated in the study and the clinical/health economics outcomes may not be solely attributable to THERAKOS ECP.
  • THERAKOS™ Photopheresis is contraindicated in:
    THERAKOS™ Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available.
  • Please refer to the THERAKOS™ CELLEX™ Photopheresis System Operator Manual for a complete list of warnings and precautions and adverse events.

Providence Medical Technology Announces FDA Clearance of CAVUX® FFS-LX Lumbar Facet Fixation System for 1- and 2-Level Lumbar Spinal Fusion

Retrieved on: 
Wednesday, January 10, 2024
Patient, MD, Nicotine, Food, Safety, FFS, FDA, Pain, DDD, PMT, Motion, Degenerative disc disease, Trial of the century

PLEASANTON, Calif., Jan. 10, 2024 /PRNewswire/ -- Providence Medical Technology, Inc. (PMT), a medical device innovator focused on improving surgical outcomes for high-risk spine surgery patients, announced that the U.S. Food and Drug Administration (FDA) has cleared its CAVUX® FFS-LX: Lumbar Facet Fixation System for use in lumbar spinal fusion surgery. 

Key Points: 
  • CAVUX® FFS-LX is a novel integrated cage and screw system that is implanted bilaterally in the facet joints to treat lumbar degenerative disc disease (DDD).
  • The implant spans the facet interspace with points of fixation at each end of the construct to offer additional stabilization for 1- or 2-level lumbar interbody fusion.
  • CAVUX® FFS-LX may be used with or without pedicle screws and rods and is implanted using the company's CORUS™ Spinal System-LX tissue-sparing access and spinal fusion system.
  • Patients who fail to fuse after a lumbar spine fusion surgery face a substantial risk of added complications, suffering, and costly revision procedures.

Equality Health Brings Proven "Medicaid-First" Value-Based Care Model to Virginia

Retrieved on: 
Wednesday, January 3, 2024
Home, Workflow, Medicare Advantage, Community, Health, PCP, News, Health equity, Commonwealth, Practitioner, VBC, Equality, Pressure, FFS

PHOENIX, Jan. 3, 2024 /PRNewswire/ -- Equality Health, a national leader in value-based care, today announced its latest expansion into the Commonwealth of Virginia, offering its proven value-based care (VBC) model to primary care providers (PCPs) and health plans throughout the state. Proudly "Medicaid-first," Equality Health aims to improve the healthcare experience of the nearly 2 million Medicaid enrollees in Virginia, while also helping participating providers advance their Medicaid, Medicare, Medicare Advantage, Exchange and commercial VBC strategies. With proprietary technology, in-practice coaching, an activity-based financial model, and community-based wraparound member support, Equality Health drives a best-in-class managed care delivery system for improved cost, quality, and health outcomes.

Key Points: 
  • PHOENIX, Jan. 3, 2024 /PRNewswire/ -- Equality Health, a national leader in value-based care, today announced its latest expansion into the Commonwealth of Virginia, offering its proven value-based care (VBC) model to primary care providers (PCPs) and health plans throughout the state.
  • With proprietary technology, in-practice coaching, an activity-based financial model, and community-based wraparound member support, Equality Health drives a best-in-class managed care delivery system for improved cost, quality, and health outcomes.
  • At the same time, Equality Health supports health plans' quality initiatives and serves as an extension to their care management teams in the community.
  • Alongside the expansion, the Equality Health Foundation will bring its community-based health and well-being programs into Virginia -- including health fairs and food-distribution events -- to advance health equity among diverse and underserved communities in the state.

Value-Based Care Benefits Patients and Physicians, New Report Shows

Retrieved on: 
Wednesday, November 15, 2023
Hospitals, Health, Practice Management, Managed Care, Health Insurance, Medicare Advantage, Human, Research, NYSE, FFS, Organization, Nursing, Pharmacist, Risk, Patient, Multimedia, Value, Emergency department, Social, Medicare, Physician, Hospital, VBC, Health insurance, Pharmaceutical industry, Medicaid, Humana

View the full release here: https://www.businesswire.com/news/home/20231115915607/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231115915607/en/
    The 2023 report shows that Medicare Advantage (MA) patients receiving care under value-based arrangements spent more time with their primary care physician and were more likely to receive preventive care, with fewer hospitalizations.
  • "As our report shows, this smarter healthcare model improves outcomes for Medicare Advantage members and allows primary care physicians to practice medicine at the top of their license and develop meaningful relationships with patients.
  • The Value-based care model (VBC) reimburses clinicians for the quality of care they provide with a focus on preventive care and better patient health outcomes.
  • Specifically, value-based care patients completed preventive screenings at a 14.6% higher rate than Medicare Advantage members not in a value-based care arrangement.

Humana Completes Aggregate $1.35 Billion Debt Offering

Retrieved on: 
Thursday, November 9, 2023
Health Insurance, Professional Services, Health, Insurance, Sale, Star, NYSE, FFS, Security (finance), J.P. Morgan & Co., Form, Privacy, Risk, Coronavirus, Government, Administration, Pharmacy, Final, Debt-to-GDP ratio, Goldman Sachs, Note, COVID-19, Prospectus, CMS, BofA Securities, Service, Judgement, Growth, Medicare, Failure, Inc., News, Information, Risk management, Health insurance, Pharmaceutical industry, Financial adviser, Humana

Humana Inc. (the “company”) (NYSE: HUM) announced today the completion of its public offering of $1.35 billion in aggregate principal amount of senior notes.

Key Points: 
  • Humana Inc. (the “company”) (NYSE: HUM) announced today the completion of its public offering of $1.35 billion in aggregate principal amount of senior notes.
  • The company expects net proceeds from the Senior Notes Offerings will be approximately $1.324 billion after deducting underwriters’ discounts and estimated offering expenses.
  • This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995.
  • Downgrades in Humana’s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.

Transform Any Spectrophotometer with FireflySci's Micro Focus Cell Conversion Kit

Retrieved on: 
Monday, December 11, 2023
Quartz, Glass, Research, FFS, DNA, Protein, Multimedia, Small business, Mobile phone, Fine chemical, Microscope

NORTHPORT, N.Y., Dec. 11, 2023 /PRNewswire-PRWeb/ -- FireflySci has been providing quartz and glass cuvettes for over ten years in the spectrophotometer industry. Their products can be found in countless labs across the United States, and they have become the go-to place for researchers' cuvette needs. FFS is a small business that focuses on customer service rather than increasing its bottom line. It is rare to find a company these days that you can call and get a live person rather than an automated message because FireflySci believes in old-fashioned, hands-on customer service.

Key Points: 
  • FireflySci is proud to release their Micro Focus Cell conversion kit which easily transforms any standard spectrophotometer into a micro-drop machine.
  • The Micro Focus Cell is a revolutionary product that can transform any spectrophotometer into a nano-sized spectrophotometer.
  • The Micro Focus Cell Conversion Kit is designed for ease of use, making the process of transforming any spectrophotometer into a nano-sized spectrophotometer straightforward and hassle-free.
  • With the Micro Focus Cell Conversion Kit, users can now get the same results as a $10,000 drop-based spectrophotometer for a fraction of the price.

Providence Medical Technology Announces New Publication Demonstrating High Fusion Rates and Successful Outcomes in Previously Failed Cervical Fusion Patients

Retrieved on: 
Thursday, December 7, 2023
Risk factor, Neck, Research, FFS, Orthopedic surgery, Duke University, Borat Subsequent Moviefilm, FUSE, Surgeon, Immobilization, Patient, Journal, ACDF, PCF, Nonunion, Success, Pain, Bleeding, Risk, Journal of Clinical Neuroscience, Hospital, Diabetes, Motion, Smoking, Birth control, Dentistry, Pharmaceutical industry, C7, C3, Neurosurgery

PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- Providence Medical Technology, Inc., a medical device innovator focused on improving surgical outcomes for high-risk spine surgery patients, today announced a new publication in the Journal of Clinical Neuroscience. Dr. Michael M. Haglund and colleagues authored the publication on the long-term outcomes of patients undergoing tissue-sparing Posterior Cervical Fusion (PCF) to revise a 1-level pseudarthrosis following a failed Anterior Cervical Discectomy and Fusion (ACDF).

Key Points: 
  • Dr. Michael M. Haglund and colleagues authored the publication on the long-term outcomes of patients undergoing tissue-sparing Posterior Cervical Fusion (PCF) to revise a 1-level pseudarthrosis following a failed Anterior Cervical Discectomy and Fusion (ACDF).
  • There are over 300,000 cervical fusion procedures performed each year, with over 40% involving patients with some form of risk factors for nonunion.
  • Our tissue-sparing posterior fusion technology is a great option to treat these patients, as is well demonstrated in this study.
  • Providence Medical Technology devices have been used to treat over 20,000 patients and are currently available in over 2,500 hospitals in the United States.

Flight Simulator Market to increase by USD 2.84 billion during 2022-2027, Rising demand for cost-effective virtual training in the aviation industry to drive the growth - Technavio

Retrieved on: 
Thursday, November 30, 2023
FFS, UAV, Berkshire Hathaway, Commercial, Airbus, PDF, Lockheed Martin, ACIS, CAE Inc., Nature, USD, Thales Group, Aircraft, Raytheon Technologies, Growth, FSTD, VIER, Textron, YOY, L3Harris Technologies, Airline, Geography

NEW YORK, Nov. 30, 2023 /PRNewswire/ -- The flight simulator market size is expected to grow by USD 2.84 billion between 2022 and 2027.

Key Points: 
  • NEW YORK, Nov. 30, 2023 /PRNewswire/ -- The flight simulator market size is expected to grow by USD 2.84 billion between 2022 and 2027.
  • The market is segmented by Product Type (Military flight simulator and Commercial flight simulator), Platform (Rotary wing simulator, Fixed wing simulator, and UAV simulator), and Geography (North America, APAC, Europe, South America, and Middle East and Africa).
  • The rising demand for cost-effective virtual training in the aviation industry drives the flight simulator market.
  • The report analyses the market size and growth and provides accurate predictions on the growth of the market.

The Oncology Institute Reports Third Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance

Retrieved on: 
Wednesday, November 8, 2023
Growth, Eastern Time Zone, FFS, Michigan House of Representatives, IV, EBITDA, Acquisition, Prescription, Date, Webcast, 2016 California Proposition 56, Clothing, Pharmaceutical industry

Third Quarter 2023 Results (for the three months ended September 30, 2023)

Key Points: 
  • Third Quarter 2023 Results (for the three months ended September 30, 2023)
    Consolidated revenue for Q3 2023 was $82.0 million, an increase of 26.3% compared to Q3 2022, and a 2.3% increase compared to Q2 2023.
  • Revenue for patient services the nine months ended 2023 was $157.3 million, up 32.4% compared to the nine months ended 2022.
  • Gross profit in the nine months ended 2023 was $45.2 million, an increase of 23.9% compared to the nine months ended 2022.
  • TOI will host a conference call and webcast on Wednesday, November 8, 2023 at 5:00 p.m. (Eastern Time) to discuss third quarter results.